Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8554012 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13422177 | 0.84 | LMNA (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19CASP3 | |
| SCHEMBL1884146 | 0.84 | CASP3 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19CASP3 | |
| SCHEMBL4437609 | 0.82 | ALDH1A1 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19CASP3 | |
| SCHEMBL29394187 | 0.82 | AADAT (0.53) | SMN1; SMN2NPC1RAB9ACASP3CASP7 | |
| SCHEMBL13209676 | 0.82 | AADAT (0.53) | SMN1; SMN2NPC1RAB9ACASP3CASP7 | |
| SCHEMBL13576750 | 0.82 | AADAT (0.53) | SMN1; SMN2NPC1RAB9ACASP3CASP7 | |
| SCHEMBL8549063 | 0.82 | TSHR (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19CASP3 | |
| SCHEMBL419527 | 0.81 | GPR119 (0.49) | SMN1; SMN2NPC1RAB9ACASP3CASP7 | |
| SCHEMBL2773331 | 0.81 | CASP3 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| CN-1972923-A | Piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | CN | disclosed |
| EP-1742934-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| US-5817677-A | ANTITHROMBOSIS AGENTS | DR. KARL THOMAE GMBH (DE) | 1998-10-06 | — | — | US | disclosed |
| EP-0858457-A1 | 5-MEMBERED HETEROCYCLES, PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AND METHODS OF PRODUCING THEM | Dr. Karl Thomae GmbH (DE) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997015567-A1 | 5-MEMBERED HETEROCYCLES, PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AND METHODS OF PRODUCING THEM | DR. KARL THOMAE GMBH (DE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | SMN1; SMN2 3570/4885NPC1 1063/4885RAB9A 1903/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | SMN1; SMN2 4083/4885NPC1 457/4885RAB9A 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.